Lecanemab, marketed as Leqembi, is a monoclonal antibody therapy for Alzheimer’s illness that targets and removes dangerous amyloid plaques whereas slowing cognitive decline. Scientists from VIB and KU Leuven have now uncovered precisely the way it works. Their analysis reveals {that a} particular a part of the antibody, often called the ‘Fc fragment’, is essential for activating microglia — the immune cells of the mind -, which then start clearing these poisonous deposits. This research gives the primary clear rationalization of how the sort of remedy features, resolving long-standing questions and providing steering for creating safer and simpler Alzheimer’s therapies. The findings have been revealed in Nature Neuroscience.
“Our research is the primary to obviously reveal how this anti-amyloid antibody remedy works in Alzheimer’s illness. We present that the remedy’s efficacy depends on the antibody’s Fc fragment, which prompts microglia to successfully clear amyloid plaques,” says Dr. Giulia Albertini, co-first creator of the research. “The Fc fragment works as an anchor that microglia latch onto when they’re close to plaques, as a consequence of which these cells are reprogrammed to clear plaques extra effectively.”
Alzheimer’s Illness and the Function of Microglia
Greater than 55 million folks worldwide dwell with Alzheimer’s illness, which is pushed by the buildup of amyloid plaques within the mind. These poisonous protein clusters harm neurons and finally result in dementia. Though microglia naturally collect round these plaques, they’re usually unable to take away them successfully. In response, researchers have been creating therapies geared toward restoring this important immune operate.
Antibody Remedy and the Fc Fragment
Lecanemab is without doubt one of the therapies designed to focus on amyloid-beta plaques and sluggish illness development, and it has already acquired FDA approval. Nonetheless, uncomfortable side effects have restricted its general profit, and till now, its actual mode of motion remained unclear.
Antibodies are made up of two major elements. One half binds to a particular goal similar to amyloid plaques, whereas the opposite half, the Fc fragment, alerts the immune system. Earlier analysis recommended that microglia play a job in clearing plaques, however direct proof linking their exercise to lecanemab’s effectiveness was lacking. Some scientists had additionally proposed that plaque removing may happen with out involvement of the Fc fragment. The crew led by Prof. Bart De Strooper demonstrated that this fragment is crucial, as microglia solely responded when it was intact and useful.
To analyze this, researchers used a specifically designed Alzheimer’s mouse mannequin that included human microglial cells. This allowed them to carefully observe how lecanemab interacts with human immune cells and promotes plaque clearance. When the Fc fragment was eliminated, the antibody not had any impact.
“The truth that we used human microglia inside a managed experimental mannequin was a significant energy of our research. This allowed us to check the very antibodies utilized in sufferers and observe human-specific responses with unprecedented decision,” provides Magdalena Zielonka, co-first creator.
Contained in the Mind’s Plaque-Clearing Course of
The crew then examined how activated microglia really take away amyloid plaques on this hybrid mannequin. They recognized key mobile processes concerned on this cleanup, together with phagocytosis and lysosomal exercise. These processes have been solely triggered when the Fc fragment was current. With out it, the microglia remained inactive.
Utilizing superior methods similar to single-cell and spatial transcriptomics, the researchers additionally recognized a particular gene exercise sample in microglia related to efficient plaque removing. This sample included robust expression of the gene SPP1 and was uncovered utilizing NOVA-ST, a technique developed by the Stein Aerts lab (VIB-KU Leuven).
Towards Safer and Extra Efficient Alzheimer’s Remedies
By defining the precise microglial program chargeable for clearing plaques, the findings level towards new methods for treating Alzheimer’s illness. Future therapies could possibly activate microglia instantly, with out counting on antibodies.
“This opens doorways to future therapies that will activate microglia with out requiring antibodies. Understanding the significance of the Fc fragment helps information the design of next-generation Alzheimer’s medicine,” concludes Prof. Bart De Strooper.
The analysis carried out on the VIB-KU Leuven Middle for Mind & Illness Analysis was supported by the European Analysis Council (ERC), Alzheimer’s Affiliation USA, Analysis Basis Flanders (FWO), Queen Elisabeth Medical Basis for Neurosciences, Stichting Alzheimer Onderzoek — Fondation Recherche Alzheimer (STOPALZHEIMER.BE), KU Leuven, VIB, and UK Dementia Analysis Institute College Faculty London.
